The widespread use of oseltamivir (Tamiflu) has been a key strategy in tackling the H1N1 ‘swine flu’ pandemic in the UK. However, there have been growing concerns about the communication of this approach and rationale behind the policy itself. In this podcast Dr Ike Iheanacho, DTB editor, discusses the policy with two members of the DTB editorial board, Dr Paul Caldwell, a general practitioner and Dr Mahdad Noursadeghi, an infectious diseases consultant. This is an extension of our September 2009 Editorial, Tamiflu − the wrong message? DTB 2009; 47: 97.